The μ-Opioid Receptor Variant N190K Is Unresponsive to Peptide Agonists yet Can be Rescued by Small-Molecule DrugsS⃞
| Autor: | Steven E. Reis, Maria Claudia Montefusco, Martin Beinborn, Inga Peter, Lei Ci, Alan S. Kopin, Carmit Goldstein, Jonathan C. Schroeder, Jean-Philippe Fortin, Gordon S. Huggins |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Agonist
Genotype medicine.drug_class Narcotic Antagonists Mutant Mutation Missense Receptors Opioid mu (+)-Naloxone Pharmacology Biology medicine.disease_cause Polymorphism Single Nucleotide Naltrexone White People Cell Line Radioligand Assay Opioid receptor Genes Reporter medicine Humans Protein Isoforms Receptor Luciferases Mutation Naloxone HEK 293 cells Cholesterol HDL Articles Enkephalin Ala(2)-MePhe(4)-Gly(5) Black or African American Protein Transport Amino Acid Substitution Opioid Peptides Mutagenesis Site-Directed Molecular Medicine Female Peptides medicine.drug Signal Transduction |
| Popis: | The μ-opioid receptor (MOR) plays an important role in modulating analgesia, feeding behavior, and a range of autonomic functions. In the current study, we investigated the degree to which 13 naturally occurring missense mutations affect the pharmacological properties of the human MOR. After expression of each receptor in human embryonic kidney 293 cells, signaling (Gαi/o-mediated) induced by peptide agonists was assessed using luciferase reporter gene assays. Multiple mutants (S66F, S147C, R260H, R265C, R265H, and S268P) show a significant reduction in agonist potency. At the N190K variant, agonist-mediated signaling was essentially absent. Enzyme-linked immunosorbent assay, microscopic analysis, and radioligand binding assays revealed that this mutant shows markedly reduced cell-surface expression, whereas all other receptor variants were expressed at normal levels. Surface expression of the N190K variant could be increased by incubation with the alkaloid agonist buprenorphine or with either naltrexone or naloxone, structurally related MOR antagonists. We were surprised to find that both putative antagonists, despite being inactive at the wild-type MOR, triggered a concentration-dependent increase in N190K receptor-mediated signaling. In contrast, peptidic ligands failed to promote expression or rescue function of the N190K mutant. Subsequent analysis of the N190K variant in an ethnically diverse cohort identified this isoform in a subgroup of African Americans. Taken together, our studies reveal that the N190K mutation leads to severe functional alterations and, in parallel, changes the response to established MOR ligands. The extent to which this mutation results in physiological abnormalities or affects drug sensitivity in selected populations (e.g., those with chronic pain or addiction) remains to be investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|